Combination GnRH antagonists for endometriosis: Balancing efficacy with side effects
- PMID: 36130483
- PMCID: PMC9512692
- DOI: 10.1016/j.xcrm.2022.100748
Combination GnRH antagonists for endometriosis: Balancing efficacy with side effects
Abstract
Endometriosis is a chronic pain condition affecting 1 in 10 women. There is an unmet need for better medical treatments for endometriosis. We spotlight trials of a single preparation combined HRT-GnRH antagonist (Relugolix) by Giudice et al.,1 for endometriosis-associated pain.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.W.H. has received honoraria for consultancy for Ferring, Roche, Nordic Pharma, and Abbvie. L.S. has received an honorarium from Gideon-Richter for attending one advisory board meeting on the use of relugolix combination therapy in the management of fibroids.
Comment on
-
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).Lancet. 2022 Jun 18;399(10343):2267-2279. doi: 10.1016/S0140-6736(22)00622-5. Lancet. 2022. PMID: 35717987 Clinical Trial.
References
-
- Giudice L.C., As-Sanie S., Arjona Ferreira J.C., Becker C.M., Abrao M.S., Lessey B.A., Brown E., Dynowski K., Wilk K., Li Y., et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) Lancet. 2022;399:2267–2279. doi: 10.1016/s0140-6736(22)00622-5. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
